Androgen receptor variants occur frequently in castration resistant prostate cancer metastases.

Although androgens are depleted in castration resistant prostate cancer (CRPC), metastases still express nuclear androgen receptor (AR) and androgen regulated genes. We recently reported that C-terminal truncated constitutively active AR splice variants contribute to CRPC development. Since specific...

Full description

Bibliographic Details
Published in:	PLoS ONE
Main Authors:	Xiaotun Zhang, Colm Morrissey, Shihua Sun, Melanie Ketchandji, Peter S Nelson, Lawrence D True, Funda Vakar-Lopez, Robert L Vessella, Stephen R Plymate
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2011-01-01
Online Access:	http://europepmc.org/articles/PMC3219707?pdf=render

Similar Items

Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling.
by: Holly M Nguyen, et al.
Published: (2013-01-01)

Mismatch repair enzyme expression in primary and castrate resistant prostate cancer
by: Belinda Nghiem, et al.
Published: (2016-10-01)

Prostate cancer characteristics associated with response to pre-receptor targeting of the androgen axis.
by: Elahe A Mostaghel, et al.
Published: (2014-01-01)

The effects of aging on the molecular and cellular composition of the prostate microenvironment.
by: Daniella Bianchi-Frias, et al.
Published: (2010-09-01)

The Interactions between Insulin and Androgens in Progression to Castrate-Resistant Prostate Cancer
by: Jennifer H. Gunter, et al.
Published: (2012-01-01)

Androgen Receptor Signaling in the Development of Castration-Resistant Prostate Cancer
by: Qin Feng, et al.
Published: (2019-09-01)

Lymphangitic Pulmonary Metastases in Castrate-Resistant Prostate Adenocarcinoma
by: Andrew Meyer, et al.
Published: (2012-01-01)

Activation of P-TEFb by Androgen Receptor-Regulated Enhancer RNAs in Castration-Resistant Prostate Cancer
by: Yu Zhao, et al.
Published: (2016-04-01)

NASP implication in the androgen receptor associated with castration resistance in prostate cancer
by: Yun Feng, et al.
Published: (2025-07-01)

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs
by: Dong Han, et al.
Published: (2024-06-01)

Dominant-negative androgen receptor inhibition of intracrine androgen-dependent growth of castration-recurrent prostate cancer.
by: Mark A Titus, et al.
Published: (2012-01-01)

AR Variant ARv567es Induces Carcinogenesis in a Novel Transgenic Mouse Model of Prostate Cancer
by: Gang Liu, et al.
Published: (2013-09-01)

Leptomeningeal Metastases in a Patient with Castration-Resistant Prostate Cancer
by: Takuya Koie, et al.
Published: (2020-01-01)

New horizons for treating castration resistant prostate cancer: Bipolar Androgen Therapy
by: Pedro Henrique Isaacsson Velho, et al.
Published: (2018-04-01)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
by: Tomasz M. Beer, et al.
Published: (2022-11-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

PREVENTION OF COMPLICATIONS IN CASTRATE-REFRACTORY PROSTATE CANCER PATIENTS WITH BONE METASTASES
by: K. M. Nushko, et al.
Published: (2015-10-01)

Androgen receptor targeted therapies in metastatic castration-resistant prostate cancer – The urologists' perspective
by: Jo-Lynn Tan, et al.
Published: (2017-12-01)

Research Progress on the Mechanism of Androgen Receptor Signaling Pathway in Castration-Resistant Prostate Cancer
by: Na Cui, et al.
Published: (2023-11-01)

CPT1A Supports Castration-Resistant Prostate Cancer in Androgen-Deprived Conditions
by: Molishree Joshi, et al.
Published: (2019-09-01)

Sox2 is an androgen receptor-repressed gene that promotes castration-resistant prostate cancer.
by: Steven Kregel, et al.
Published: (2013-01-01)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)

Glucocorticoid receptor and androgen receptor-targeting therapy in patients with castration-resistant prostate cancer
by: Sahyun Pak, et al.
Published: (2022-09-01)

Risk or Protective Factors of Prostate Cancer Progressing to Castration Resistant Prostate Cancer After Androgen Deprivation Therapy
by: CHEN Chiwei, et al.
Published: (2020-07-01)

Druggable Metabolic Vulnerabilities Are Exposed and Masked during Progression to Castration Resistant Prostate Cancer
by: Stephen Y. C. Choi, et al.
Published: (2022-10-01)

Modern antiandrogenic therapy of patients with castration-resistant prostate cancer without metastases
by: S. V. Popov
Published: (2020-12-01)

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
by: A. D. Kaprin, et al.
Published: (2018-07-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Sipuleucel-T and Androgen Receptor-Directed Therapy for Castration-Resistant Prostate Cancer: A Meta-Analysis
by: Renliang Yi, et al.
Published: (2016-01-01)

Androgen receptor-mediated downregulation of microRNA-221 and -222 in castration-resistant prostate cancer.
by: Bin Gui, et al.
Published: (2017-01-01)

Therapeutic Potential of Bipolar Androgen Therapy for Castration-Resistant Prostate Cancer: In Vitro and In Vivo Studies
by: Jiwoong Yu, et al.
Published: (2024-01-01)

PROTACs targeting androgen receptor signaling: Potential therapeutic agents for castration-resistant prostate cancer
by: Yulu Zhang, et al.
Published: (2024-07-01)

Complete androgen blockade safely allows for delay of cytotoxic chemotherapy in castration refractory prostate cancer
by: Rafael A. Kaliks, et al.
Published: (2010-06-01)

Selective androgen receptor degrader (SARD) to overcome antiandrogen resistance in castration-resistant prostate cancer
by: Meng Wu, et al.
Published: (2023-01-01)

Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7
by: Balaji Chandrasekaran, et al.
Published: (2023-03-01)

Genomic and transcriptomic features of androgen receptor signaling inhibitor resistance in metastatic castration-resistant prostate cancer
by: Xiaolin Zhu, et al.
Published: (2024-10-01)

Patient-Derived Xenografts and Organoids Recapitulate Castration-Resistant Prostate Cancer with Sustained Androgen Receptor Signaling
by: Annelies Van Hemelryk, et al.
Published: (2022-11-01)

Clinical characteristics of patients with metastatic castration-resistant prostate cancer after treatment with combined androgen blockade
by: Daisuke Obinata, et al.
Published: (2023-04-01)

Correction: Cabozantinib Inhibits Growth of Androgen-Sensitive and Castration-Resistant Prostate Cancer and Affects Bone Remodeling.
Published: (2014-01-01)

A compendium of Androgen Receptor Variant 7 target genes and their role in Castration Resistant Prostate Cancer
by: Katie Joanna Miller, et al.
Published: (2023-03-01)